Is SCLX or SGMO more undervalued in 2026?

CirclFi compares Scilex Holding Company (SCLX) and Sangamo Therapeutics, Inc. (SGMO) using 13 institutional-grade valuation models. SCLX has a Quality of Company score of 4.7/10 while SGMO scores 5.2/10.

Which is a better buy — SCLX or SGMO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SCLX and SGMO valuations compare?

SCLX at $8.90 and SGMO at $0.22 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SCLX vs SGMO Valuation Comparison 2026 — Intrinsic Value Analysis

SCLX

Biological Products, (No Diagnostic Substances)

Scilex Holding Company

Quality

4.7

out of 10

Value Trap

WARN

Price

$8.90

Last close

Models

5/13

Active

SGMO

Biological Products, (No Diagnostic Substances)

Sangamo Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

LOW

Price

$0.22

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	SCLX Fair Value	SCLX Upside	SGMO Fair Value	SGMO Upside
Bayesian DCF	Intrinsic	$33.36	+463.5%	$0.03	-84.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	—	—	$0.46	+110.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$13.55	+52.2%	—	—

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SCLX vs SGMO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SCLX vs SGMO — Which Stock Is More Undervalued?

SGMO scores higher with a 5.2/10 quality rating vs SCLX's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Scilex Holding Company (SCLX) and Sangamo Therapeutics, Inc. (SGMO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SCLX currently trades at $8.90 with a QOC of 4.7/10, while SGMO trades at $0.22 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).